Novo Nordisk (NYSE:NVO) shares fell more than 5% yesterday, following comments from the President-elect regarding drug prices and a lawsuit alleging that the Danish diabetes giant made misleading earning forecasts.
The securities class action lawsuit against Nordisk also named Eli Lilly (NYSE:LLY), Sanofi (NYSE:SNY) and Merck (NYSE:MRK), claiming that Nordisk’s reported earnings and forecasts were inflated through price fixing for the company’s insulin drugs.
Get the full story at our sister site, Drug Delivery Business News.